Member Info for jezza1977

The next cohort of patients will validate hgct1. and i think SP action begins as soon as the first injection is made. as the safety profile of hgct1 begins to replicate the first cohort (all being well) things get very real very quickly. imo. good luck all.

Ive said before, you dont need to know much about any stock to trade it. And it gets a little bit embarrassing when such traders try to claim they know things.

know your limits as the fast show used to say.

Positions being taken pre-injection of next patient. let the action begin.

One4one, do you think phase 1b is part of phase 1 or phase 2?

I have not researched avacta. i have spent a lot of time in the last year and a half researching hemo.

i have no idea about avacta. very clear to me you have no idea about hemo.

but good luck.

Alde, anyone with any sense knows that once the trial begins again then further milestones of patient safety will roll through rapidly. a clear picture will begin to form.

3 patients first cohort

up to 5 safety data within 6 weeks lets say

then up to 7 patients another 4 or 5 weeks

and up to 9 and we're still in the Summer.

The value here if the safety profile continues to replicate will explode. IMO.

Still dumbfounded how a pharma can be in trial for a CAR T treatment for a deadly disease with such encouraging results to date and yet be worth less than £50m. lets see if things change as the trial restarts and - all being well - safety continues to be cleared for each patient. i look forward to the summer.

Pumpky, via the share options awarded as per the RNS that everyone has been commenting on all week? you understand they give him exposure to any SP growth above the strike price dont you?

Anyone can get share options if they so wish, easy. Just be very clever (a tricky hurdle for starters), educated and hard working, set up your own company, invent a new cancer treatment, work on it for 10 year+ and then the worlds your oyster.

Ill admit i am moderately intersted in your trading commentary Alde. however Im not sure you hve the first idea what will encourage big pharma to make a move on hgct1. with all due respect id stick to guessing on avacta where i think you do have more of an idea.

I know lots of people use charts so this is interesting info. see what happens over the coming days building up to injection of next patients. i think we just need some volume now.

2 things i noted from the presentation (sorry if someone else highlighted them)

page 2 - CAR T expansion and persistence observed

page 13 starred footnote - Potential to accelerate into Phase II if no DLT in three cohorts and efficacy signal

persistence = evidence of t cells for a period post injection

phase 2 could commence after three cohorts if safe and working - 3x3 patients.

positive stuff.

Alde, add no big debt to that as well and full ownership of the assets.

sorry for double posting btw.

"LTL fair assessment lol

Yes maybe I am too negative and distrusting. Im battle scarred after years of trying to invest in smallcaps.

I have said a few positive things about hemo. I do believe and have proved through my calculations (right or wrong), that it is undervalued. I do believe the science is promising. I do think the low share count (if it stays that way) is a great plus point and their is very large upside.

Ill end it there"

That presentation is a pleasant read. maybe it was put together for the £3m funders. nothing new on it really but its nice to be reminded of the high level science going on. a suite of products with platform potential.

That presentation is a pleasant read. maybe it was put together for the £3m funders. nothing new on it really but its nice to be reminded of the high level science going on. a suite of products with platform potential.

Based on the how the data was presented id say they were single occurences.

hinted from the 36 non treatment related issues. there are not 36 patients from my memory.

Course you would. tantrum sellers showing their face. whatever it is it was not deemed serious enough to be classed as a DLT though so imo it doesnt really matter.

There are pros and cons. some saying the options are too much, too low a price, some acknowledging it incentives the board.

not sure anyones ramping it. i wasnt sure you were being serious.

Who cares what avacta do? here tangible progress is the next injection of p4. and commencing the paediatric arm which is v exciting. now the directors are properly incentivised to deliver we migt get moving properly.

Thanks DaddyBear.

Im in for the big bucks. i believe HEMO have the goods and Vlads science is top notch. Its as simple as that. as a result i dont need to worry about the price gong up or down now.

buy, hold, sell, wait, moan, i dont care what anyone else does.